Malaria Vaccine: Finally a Turning Point ?

By Ana Espino | Published on April 23, 2026 | 4 min read


Malaria remains a major infectious disease, responsible for hundreds of millions of cases and around 600,000 deaths each year, mainly among young children in Africa. Despite existing prevention and treatment strategies, such as mosquito nets, insecticides, and antimalarial therapies, their effectiveness is limited by the emergence of resistance, both in the parasite and in mosquito vectors.

The development of vaccines appears to be a promising solution for sustainable disease control. However, several limitations hinder their effectiveness. The biological complexity of the Plasmodium parasite, characterized by a multi-stage life cycle with distinct antigens, as well as its high genetic variability, makes it difficult to induce broad and durable immunity. Moreover, natural immunity is often partial and short-lived, complicating the identification of effective vaccine targets. Practical constraints, such as vaccine stability, multi-dose schedules, and logistical challenges in resource-limited countries, also represent major obstacles.

In this context, the main challenges involve developing vaccines capable of providing long-lasting protection, effective across all stages of the parasite, and suitable for different populations.

The objective of this study is to provide an overview of malaria vaccines by analyzing recent advances, particularly the approved vaccines RTS,S and R21, as well as new strategies and technologies under development to improve their effectiveness.

A truly effective vaccine: myth or reality ?

The article is based on a review of recent scientific literature on malaria vaccines, including data from preclinical and clinical trials. The analysis covers currently available vaccines, candidates under development targeting different stages of the parasite, and technological innovations in vaccine platforms and adjuvants.

The results show that two vaccines have recently been approved by the WHO for the prevention of Plasmodium falciparum malaria in children: RTS,S and R21. The RTS,S vaccine shows moderate efficacy, around 30–50% depending on populations and vaccination schedules, with protection decreasing over time. The more recent R21 vaccine shows more promising results, with efficacy reaching around 75% at one year, although the duration of long-term protection remains to be confirmed.

In addition, many vaccines are currently under development. These target different stages of the parasite’s life cycle: pre-erythrocytic vaccines aim to prevent initial infection, blood-stage vaccines seek to reduce disease severity, and transmission-blocking vaccines act within the mosquito to interrupt the infectious cycle. Some candidates, such as those targeting the RH5 or Pfs230 antigens, show promising immunological responses, although their clinical efficacy still needs to be confirmed.

Finally, the emergence of new technologies offers significant prospects. mRNA vaccines, nanoparticles, and new adjuvants can enhance immune responses and may overcome current vaccine limitations, particularly in terms of immunogenicity and duration of protection. However, these approaches still face logistical and economic challenges, especially regarding storage and distribution.

Toward a game-changing vaccine

Malaria remains a major infectious disease requiring innovative strategies for effective control. The main challenges identified include the complexity of the parasite, variability in immune responses, the limited duration of protection provided by current vaccines, and logistical constraints related to their deployment.

The aim of this study was to review progress in malaria vaccine development. The results show that, despite significant advances with RTS,S and R21, protection remains partial and still insufficient for global eradication.

The study highlights several limitations, including the lack of vaccines providing both durable and universal protection, as well as difficulties associated with evaluating long-term efficacy and large-scale deployment. In this context, future perspectives rely on the development of multi-stage vaccines combining multiple antigens, the integration of new technologies such as mRNA vaccines and nanoparticles, and improvements in adjuvants.




About the author – Ana Espino
PhD in Immunology, specialized in Virology  
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions through impactful communication.